Australia -
engelsk -
Department of Health (Therapeutic Goods Administration)
mabthera sc rituximab (rch) 1400 mg/11.7 ml solution for injection vial
roche products pty ltd - rituximab, quantity: 1400 mg - injection - excipient ingredients: vorhyaluronidase alfa; histidine; histidine hydrochloride; trehalose dihydrate; methionine; polysorbate 80; water for injections - mabthera sc is indicated for treatment of patients with: - cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin's lymphoma, - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma, - cd 20 positive, diffuse large b-cell non-hodgkin's lymphoma, in combination with chemotherapy.
Storbritannia -
engelsk -
MHRA (Medicines & Healthcare Products Regulatory Agency)
hyqvia 2.5g25ml solution for infusion and 1.25ml vials
baxalta uk ltd - not applicable
Storbritannia -
engelsk -
MHRA (Medicines & Healthcare Products Regulatory Agency)
hyqvia 5g50ml solution for infusion and 2.5ml vials
baxalta uk ltd - not applicable
Storbritannia -
engelsk -
MHRA (Medicines & Healthcare Products Regulatory Agency)
hyqvia 10g100ml solution for infusion and 5ml vials
baxalta uk ltd - not applicable
Storbritannia -
engelsk -
MHRA (Medicines & Healthcare Products Regulatory Agency)
hyqvia 20g200ml solution for infusion and 10ml vials
baxalta uk ltd - not applicable
Storbritannia -
engelsk -
MHRA (Medicines & Healthcare Products Regulatory Agency)
hyqvia 30g300ml solution for infusion and 15ml vials
baxalta uk ltd - not applicable
Israel -
engelsk -
Ministry of Health
hyqvia
takeda israel ltd - human normal immunoglobulin - solution for infusion - human normal immunoglobulin 100 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - replacement therapy in adults, children and adolescents (0-18 years) in:• primary immunodeficiency syndromes with impaired antibody production • hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (cll), in whom prophylactic antibiotics have failed or are contra-indicated.• hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (mm) patients.• hypogammaglobulinaemia in patients pre- and post-allogeneic hematopoietic stem cell transplantation (hsct).
Den europeiske union -
engelsk -
EMA (European Medicines Agency)
hyqvia
baxalta innovations gmbh - human normal immunoglobulin - immunologic deficiency syndromes - immune sera and immunoglobulins, - replacement therapy in adults, children and adolescents (0-18 years) in:primary immunodeficiency syndromes with impaired antibody production.hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (cll), in whom prophylactic antibiotics have failed or are contra‑indicated.hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (mm) patients.hypogammaglobulinaemia in patients pre‑ and post‑allogeneic hematopoietic stem cell transplantation (hsct).
Australia -
engelsk -
Department of Health (Therapeutic Goods Administration)
sydney ivf hyaluronidase - in vitro fertilization culture medium kit
william a cook australia pty ltd -
USA -
engelsk -
NLM (National Library of Medicine)
viatrexx-mesenchyme- adrenal, ascorbic acid, bdnf, dhea, malic acid, bfgf, fucus vesiculosus, histidine, hyaluronidase, il-6, la
viatrexx bio incorporated - bos taurus adrenal gland (unii: m2776swb29) (bos taurus adrenal gland - unii:m2776swb29), sus scrofa adrenal gland (unii: 398iyq16yv) (sus scrofa adrenal gland - unii:398iyq16yv), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), brain-derived neurotrophic factor human (unii: 7171wsg8a2) (brain-derived neurotrophic factor human - unii:7171wsg8a2), prasterone (unii: 459ag36t1b) (prasterone - unii:459ag36t1b), malic acid (unii: 817l1n4ckp) (malic acid - unii:817l1n4ckp), basic fibrobla - to help encourage extra cellular / matrix / connective tissue drainage & support.